Investing.com -- Shares in Eurofins Scientific (EPA:EUFI) rose on Tuesday, paring back some losses posted in the prior session, after the French laboratory group rejected short seller Muddy Waters' (NYSE:WAT) accusations that it had misrepresented its financial statements. On Monday, Muddy Waters said it was short Eurofins, citing "confusion and contradictions" in the company's operations that led it to believe Eurofins was "optimized for malfeasance, rather than for conventional business." In particular, Muddy Waters claimed Eurofins' financial disclosures contained "material overstatements" of its profits, cash balances and other asset values. However, Eurofins, which provides testing and support services to firms across a number of industries, dismissed the allegations, calling them "blatantly wrong and/or misleading." They added that Muddy Waters has "never participated" in its investor events and has not engaged with Eurofins to discuss the "correctness or relevance of their assumptions, hypotheses and inferences." "Upon a first review of their claims, it is Eurofins’ view that the entirety of the allegations and insinuations contained therein is either inaccurate, irrelevant, biased and/or misleading," Eurofins said in a statement. It noted that it would release a more detailed response in "due course" and will work with auditors to prepare "further analyses as required." In the wake of Muddy Waters' report, shares in Eurofins shed as much as 25% of their value on Monday. Related Articles Eurofins Scientific shares rise as laboratory group denies Muddy Waters claims Venezuela international bondholders hire legal advisors for restructuring Lufthansa raises ticket prices to meet environmental requirements
Eurofins Scientific shares rise as laboratory group denies Muddy Waters claims
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...